Evidence map›Paper›PMID 40878384›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Reprogramming of Fatty Acid Metabolism via PPARα-Orchestrated FADS2 in Keratinocytes Modulates Skin Inflammation in Psoriasis.

Jiangluyi Cai, Xue Zhou, Yu Zhuang, Lian Cui, Rui Ma, Youdong Chen, Nan Yang, Qianyu Chen, Yuanyuan Wang, Peiyao Zhu and 10 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. CEACAM5 drives psoriatic inflammation by regulating CD8Biochemistry and biophysics reports · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Enzyme-AssistedInternational journal of molecular sciences · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Frontiers in pharmacology · 2026
    Article
  13. Mechanisms and active components ofFrontiers in immunology · 2026
    Article
  14. Therapeutic effect ofFrontiers in pharmacology · 2026
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jiangluyi CaiDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Xue ZhouDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Yu ZhuangDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Lian CuiDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Rui MaDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Youdong ChenDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Nan YangDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Qianyu ChenDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Yuanyuan WangDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Peiyao ZhuDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Lingling YaoDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Qian YuDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Xiaomin SheDepartment of Dermatology, Shanghai Tenth People's Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200072, China.
Xuyang ZhouDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Yuemeng HuangDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Zengyang YuDepartment of Dermatology, Shanghai Tenth People's Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200072, China.
Xilin ZhangDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Jiajing LuDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.
Yuling ShiDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.ORCID https://orcid.org/0000-0002-1273-7881
Chunyuan GuoDepartment of Dermatology, Shanghai Skin Disease Hospital, Institute of Psoriasis, Tongji University School of Medicine, Shanghai, 200443, China.ORCID https://orcid.org/0000-0001-6769-1713

Funding

Clinical Research Plan of SHDC No.SHDC22022302Innovation Program of Shanghai Municipal Education Commission 2025GDZKZD06National Key Research and Development Program of China 2023YFC2508106National Natural Science Foundation of China 82273525:82430101:82273510:82273515:81900612:82103712Research Program of Shanghai Skin Disease Hospital No. 2019KYQD08Shanghai Dermatology Research Center 2023ZZ02017
6 · The paper itself

Abstract

Psoriasis is a chronic inflammatory skin disorder characterized by keratinocyte hyper-proliferation and immune dysregulation. Recent evidence has implicated dysregulated polyunsaturated fatty acid (PUFA) metabolism in its pathogenesis. In this study, fatty acid desaturase 2 (FADS2), the rate-limiting Δ6-desaturase in PUFA biosynthesis, is identified as a central regulator of psoriatic inflammation. FADS2 expression is consistently reduced in keratinocytes from patients with psoriasis and in mouse models. Keratinocyte-intrinsic Fads2 knockdown exacerbates imiquimod-induced psoriasis-like dermatitis, which is marked by enhanced neutrophil recruitment and NF-κB activation, whereas Fads2 overexpression exerts protective effects and alleviates skin inflammation. In vitro, FADS2 knockdown in keratinocytes enhances M5-induced pro-inflammatory cytokine production, whereas FADS2 overexpression attenuates these effects. Lipidomic analysis reveals that impaired docosahexaenoic acid (DHA) biosynthesis is a key downstream consequence of FADS2 deficiency. Mechanistically, loss of FADS2 disrupts DHA biosynthesis, thus promoting an inflammatory response accompanied by increased NF-κB phosphorylation in keratinocytes to attract neutrophils. Furthermore, PPARα is identified as an upstream transcriptional activator of FADS2, and pharmacological activation of PPARα alleviates psoriatic inflammation in a FADS2-dependent manner. Together, these findings uncover a PPARα-FADS2-DHA-NF-κB axis that links lipid metabolism to immune regulation in psoriasis, highlighting a potential therapeutic strategy for restoring cutaneous immune homeostasis.

Indexed as

Fatty Acid DesaturasesFatty AcidsInflammationKeratinocytesPPAR alphaPsoriasisAnimalsDisease Models, AnimalHumansMiceNF-kappa BSkinFADS2 protein, humanFatty Acid DesaturasesFatty AcidsNF-kappa BPPAR alphaFADS2fatty acidinflammationkeratinocytesPPARαpsoriasis

Identifiers

PMID40878384
PMCPMC12561275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.